Please login to the form below

Not currently logged in
Email:
Password:

Lisocabtagene maraleucel

This page shows the latest Lisocabtagene maraleucel news and features for those working in and with pharma, biotech and healthcare.

Yescarta gains first FDA approval for indolent follicular lymphoma

Yescarta gains first FDA approval for indolent follicular lymphoma

Also approved for the treatment of large B-cell lymphoma is Novartis’ rival CAR-T therapy Kymriah (tisagenlecleucel) and Bristol Myers Squibb’s (BMS) Breyanzi (lisocabtagene maraleucel), which are both approved

Latest news

More from news
Approximately 1 fully matching, plus 14 partially matching documents found.

Latest Intelligence

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    Liso-cel (lisocabtagene maraleucel, JCAR-017) is an immunotherapy comprised of autologous T cells genetically modified (via lentiviral vector) to express an anti-CD19 chimeric antigen receptor (CAR).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....